Sign In
Buy SDZNY
$79.34
-0.468 (-0.586%)
At Close: Jun 03, 2026
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
01:40am, Wednesday, 30'th Jul 2025
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing cap
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300
EU-US trade deal could add up to $19 billion in pharma industry costs, analysts say
01:42pm, Monday, 28'th Jul 2025
The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
10:31am, Monday, 09'th Jun 2025
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosuma
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
11:30am, Wednesday, 21'st May 2025
MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
12:46pm, Tuesday, 06'th May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents i
Sandoz Group AG (SDZNY) Q1 2025 Earnings Call Transcript
03:57pm, Friday, 02'nd May 2025
Sandoz Group AG (OTCQX:SDZNY) Q1 2025 Results Conference Call April 30, 2025 3:00 AM ET Company Participants Craig Marks - Head of Investor Relations Richard Saynor - Chief Executive Officer Remco Ste
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
01:00am, Wednesday, 30'th Apr 2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a com
MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius t
Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
08:46am, Monday, 28'th Apr 2025
The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
07:51am, Tuesday, 15'th Apr 2025
Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financ
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
10:00am, Monday, 14'th Apr 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated
Switzerland's Sandoz files antitrust lawsuit against Amgen in US
01:13am, Monday, 14'th Apr 2025
Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
01:00am, Monday, 14'th Apr 2025
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infl
